靶向TRPV4-RhoA-RhoGDI1轴灭活RhoA治疗高血压
该研究揭示AH001通过靶向TRPV4-RhoA-RhoGDI1轴将失活RhoA-GDP隔离于质膜和胞质,从而抑制RhoA信号通路。在Ang II诱导的高血压小鼠和自发性高血压大鼠中,AH001降低急性和长期血压并预防血管重塑,该效应在Trpv4-/-和平滑肌特异性RhoGDI1敲除小鼠中减弱。
要点
- AH001靶向TRPV4-RhoA-RhoGDI1轴,隔离失活RhoA-GDP,不同于典型RhoA抑制模式
- AH001在Ang II高血压小鼠和SHR中降低急性和长期血压并预防血管重塑
- AH001经RhoA/ROCK/MYPT1/MLC抑制VSMC收缩,经RhoA/ROCK/LIMK1通路抑制表型转化
核心结论
- 研究揭示靶向TRPV4-RhoA-RhoGDI1轴灭活RhoA的新型信号抑制模式,为抗高血压药物开发提供新思路。
研究设计与样本
- 采用冷冻电镜、邻位连接 assay 和定点诱变探索RhoA活性调控机制。
- 使用VSMC、高血压动物模型、Trpv4-/-小鼠和平滑肌特异性RhoGDI1敲除(Arhgdiaf/f Myh11-CREERT2)小鼠研究该轴在高血压中的作用。
主要发现
- AH001被鉴定为RhoA信号通路新型抑制剂,靶向TRPV4-RhoA-RhoGDI1轴将失活RhoA-GDP隔离于质膜和胞质。
- TRPV4AH001-RhoA复合物冷冻电镜结构显示AH001结合的TRPV4呈闭合状态,RhoA呈失活GDP结合状态。
- AH001通过增强VSMC中TRPV4-RhoA结合和促进RhoGDI1-RhoA相互作用减少活性RhoA池。
- AH001在Ang II诱导高血压小鼠和自发性高血压大鼠中降低急性和长期血压并预防血管重塑,但在Trpv4-/-和Arhgdiaf/f Myh11-CREERT2小鼠中减弱。
- AH001经RhoA/ROCK/MYPT1/MLC通路抑制VSMC收缩,经RhoA/ROCK/LIMK1/cofilin/MRTF-A/SRF通路抑制VSMC向肌成纤维细胞表型转化。
临床怎么用
- AH001代表靶向TRPV4-RhoA-RhoGDI1轴灭活RhoA的新型抗高血压策略,待未来药物开发验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The RhoA (Ras homolog family member A) signaling pathway is pivotal in regulating vascular smooth muscle cells (VSMCs) function and blood pressure homeostasis. Current inhibitors of the RhoA signaling pathway are limited in hypertension treatment, suffering from poor efficacy, insufficient specificity, and developmental challenges. METHODS: Cryo-electron microscopy (EM), proximity ligation assay (PLA), and site-directed mutagenesis were used to explore the mechanism of RhoA activity regulation. VSMC, hypertensive animal models, Trpv4-/- and Arhgdiaf/f Myh11-CREERT2 (smooth muscle-specific RhoGDI1 knockout) mice were used to investigate the role of the TRPV4 (transient receptor potential cation channel subfamily V member 4)-RhoA-RhoGDI1 (Rho GDP dissociation inhibitor 1) axis in hypertension. RESULTS: AH001 ((R)-1-(3-ethylphenyl) ethane-1,2-diol) was identified as a novel inhibitor of the RhoA signaling pathway. It targets the TRPV4-RhoA-RhoGDI1 axis to effectively sequester inactive RhoA-GDP in the plasma membrane and cytoplasm, which is distinct from typical RhoA inhibition modes. The cryo-EM structure of the TRPV4AH001-RhoA complex showed that AH001-bound TRPV4 adopts a closed state with RhoA in an inactive GDP-bound state. Functional studies further revealed that AH001 reduced the pool of active RhoA by enhancing TRPV4-RhoA binding and facilitating RhoGDI1-RhoA interaction in VSMC. This inhibition notably decreased both acute and long-term blood pressure and prevented vascular remodeling in Ang II-induced hypertensive mice and spontaneously hypertensive rats. However, these antihypertensive effects were weakened in Trpv4-/- and Arhgdiaf/f Myh11-CREERT2 mice. Additionally, AH001 effectively inhibited VSMC contraction via the RhoA/ROCK (Rho-associated protein kinase)/MYPT1 (myosin phosphatase target subunit 1)/MLC (myosin light chain 2) signaling pathway and suppressed VSMC phenotype switching to myofibroblasts through the RhoA/ROCK/LIMK1 (LIM domain kinase)/cofilin/MRTF-A (myocardin-related transcription factor A)/SRF (serum response factor) signaling cascade. TRPV4 and RhoGDI1 knockdown attenuated AH001's inhibition of VSMC contraction and phenotypic switching to myofibroblasts. CONCLUSIONS: This study revealed a novel mode of RhoA signaling inhibition targeting the TRPV4-RhoA-RhoGDI1 axis, offering new insights for future antihypertensive drug development and proposing innovative strategies for targeting challenging Rho GTPases.
引用
- Wang J, Yuan Z, Yu N, et al. Inactivation of RhoA for Hypertension Treatment Through the TRPV4-RhoA-RhoGDI1 Axis. Circulation. 2025. PMID: 40518994. doi:10.1161/CIRCULATIONAHA.124.071884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。